- Previous Close
0.0000 - Open
0.0004 - Bid 0.0040 x --
- Ask 0.0289 x --
- Day's Range
0.0004 - 0.0004 - 52 Week Range
0.0004 - 0.0390 - Volume
20 - Avg. Volume
0 - Market Cap (intraday)
3.087M - Beta (5Y Monthly) -76.01
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date Apr 7, 2025 - Apr 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It is developing RASP-201, a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase, a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301, an NCE for NPM1, currently at the pre-clinical stage to treat refractory AML with reduced toxicity. The company was formerly known as Rasna Therapeutics, Inc. and changed its name to Actavia Life Sciences, Inc. in October 2023. Actavia Life Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
www.rasna.comRecent News: RASP
View MorePerformance Overview: RASP
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RASP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RASP
View MoreValuation Measures
Market Cap
3.09M
Enterprise Value
3.39M
Trailing P/E
4.87
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-427.68%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-406.65k
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.39k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
6.9k